Drugs / VO659
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05822908 | Feb 2023 → Apr 2028 expected | Huntington disease, Machado-Joseph disease, spinocerebellar ataxia type 1 | Vico Therapeutics B. V. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VO659 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05822908 ↗ |
| Action | Inhibit | “reducing the intracellular level of the harmful mutant proteins” NCT05822908 ↗ |
| Modality | Antisense oligonucleotide | “VO659 is an antisense oligonucleotide targeting CAG repeats in mRNA transcripts” NCT05822908 ↗ |
| Route | Intrathecal | “Study drug will be administered by lumbar intrathecal bolus injections.” NCT05822908 ↗ |